Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmeisORPEF 53 EV-to-EBITDA is 13.92 as of Jul. 22, 2026, which is 13% below its 10-year median of 16.00. GuruFocus rates ORPEF with a GF Score™ of 53/100 and a GF Value™ of $9.51. The stock has 8 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Emeis ranks worse than 61.66% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Emeis's enterprise value is $11,988 Mil.
Emeis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $861 Mil. Therefore, Emeis's EV-to-EBITDA for today is 13.92.
The historical rank and industry rank for Emeis's EV-to-EBITDA or its related term are showing as below:
ORPEF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.78 Med: 16 Max: 30.12
Current: 14.19
During the past 13 years, the highest EV-to-EBITDA of Emeis was 30.12. The lowest was -3.78. And the median was 16.00.
ORPEF's EV-to-EBITDA is ranked worse than 61.66% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.075
vs ORPEF: 14.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-22), Emeis's stock price is $14.22.
Emeis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.151. Therefore, Emeis's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Emeis (OTCPK:ORPEF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Emeis's share price for today is $14.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Emeis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.151.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Emeis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Emeis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emeis EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emeis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Emeis's EV-to-EBITDA falls into.
Emeis's current Enterprise Value is $11,988 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Emeis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $861 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emeis (ORPEF) has a EV-to-EBITDA of 13.92 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Emeis. This is 13% below median its historical median of 16.00. According to the industry distribution chart, Emeis ranks #312 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 61.7%.
Is Emeis' EV-to-EBITDA too high?
Emeis' current EV-to-EBITDA of 13.92 is 13% below median its 10-year median of 16.00. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.08. Emeis' value of 13.92 is 25.7% above this industry median. Based on the distribution chart, Emeis ranks #312 out of 506 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Emeis has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Emeis' EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Emeis ranks #312 out of 506 companies for EV-to-EBITDA. This places Emeis in the lower half of its industry. The industry median EV-to-EBITDA is 11.08. Emeis' value of 13.92 is 25.7% above this benchmark. While the company's 10-year median is 16.00 vs. the industry median of 11.08, Emeis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.08, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emeis's current EV-to-EBITDA of 13.92 is 25.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Emeis. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emeis's current EV-to-EBITDA is 13.92, which is 13% below median its own 10-year median of 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emeis stock overvalued right now?
Emeis (ORPEF) has a current EV-to-EBITDA of 13.92. The stock's GF Value™ is $9.51, compared to a current price of $14.22 — trading 49.5% above its estimated fair value. The current EV-to-EBITDA is 13.92, which is 13% below median its 10-year median of 16.00 and 25.7% above the Healthcare Providers & Services industry median of 11.08. Emeis' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Emeis (ORPEF), the current EV-to-EBITDA is 13.92 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emeis (ORPEF) Overvalued in 2026?
Based on GuruFocus' analysis, Emeis stock appears to be overvalued.
The current stock price of $14.22 is trading 49.5% above its estimated GF Value™ of $9.51.
Key valuation signals for ORPEF:
EV-to-EBITDA: 13.92 (13% below median its 10-year median of 16.00)
GF Value™: $9.51 vs. price of $14.22 (49.5% above fair value)
Industry Position: 25.7% above the Healthcare Providers & Services median (#312 of 506)
No single metric tells the full story. See the ORPEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emeis operates a comprehensive care offering of mental health clinics and medical and rehabilitation care, retirement homes, assisted living and home care.
53GF Score
Get the complete analysis for ORPEF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPEF has been successfully added to your 
